|Bid||172.20 x 6700|
|Ask||172.25 x 11200|
|Day's Range||168.60 - 174.95|
|52 Week Range||142.80 - 231.50|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||23.53|
|Earnings Date||Aug 04, 2022|
|Forward Dividend & Yield||1.85 (1.07%)|
|Ex-Dividend Date||Apr 25, 2022|
|1y Target Est||219.00|
Subscribe to Yahoo Finance Plus to view Fair Value for MRK.DE
FRANKFURT (Reuters) -Germany's Merck KGaA expects strong earnings growth this year as its laboratory gear division benefits from drugmakers' efforts to explore new biotechnologies, even as demand related to COVID-19 has probably reached its peak. "Life Science will remain the strongest growth engine for Merck," said the company, which also makes pharmaceuticals and speciality chemicals for semiconductor manufacturers. Fourth-quarter adjusted EBITDA rose 17.6% to 1.46 billion euros ($1.62 billion), slightly below an analyst consensus of 1.48 billion euros posted on Merck's website.
German supplier of chemicals and materials used in making semiconductors, Merck KGaA, announced on Tuesday it is to invest 500 million euros in Taiwan over the next five to seven years, primarily in semiconductor technologies. Merck said it would be its largest investment in Taiwan since it established operations there in 1989. "We strengthen our local production and new capabilities to support fast-growing semiconductor demand in Taiwan but also to cater to an increasing demand in the rest of the world," Beckmann said, adding that the investment would expand Merck's footprint in the island's southern city of Kaohsiung. Merck's announcement follows that of Taiwan Semiconductor Manufacturing Co Ltd (TSMC) last month, when the world's largest contract chip maker said it will set up a new chip factory in Kaohsiung to boost production amid a global chip shortage.